One notable recent example of progress in the use of CAR T-cells to treat pediatric CNS tumors has been the use of intracranially-infused (e.g. locoregional) B7-H3-directed CAR T-cells for children with r/r CNS tumors or diffuse intrinsic pontine gliomas (DIPGs), e.g. the BrainChild-03 clinical trial (NCT04185038).135. This evidence concerns the gene CD276 and central nervous system neoplasm.